NCT00681551View on ClinicalTrials.gov

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

March 31, 2004

Conditions
Brain Neoplasms
Interventions
DRUG

Magnevist (SH L 451A)

Magnevist at a dose of 0.1 mmol/kg

DRUG

Magnevist (SH L 451A)

Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.

Trial Locations (9)

222-0036

Yokohama

530-8480

Osaka

537-8511

Osaka

430-8558

Hamamatsu

113-8677

Bunkyo-ku

145-0065

Ōta-ku

141-8625

Shinagawa-ku

162-8666

Shinjuku-ku

409-3898

Nakakoma-gun

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY